6APRIL - 2023TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comSince the invention of the first FDA-approved immune checkpoint inhibitor in 2011, the field of immunotherapy is growing exponentially. Multiple immunotherapeutic approaches dedicated to cancer vaccines, adoptive cell therapies, monoclonal antibodies, cytokine therapies, oncolytic viruses, and inhibitors targeting immune checkpoints are currently in development. Many of these approaches are already approved for specific cancer treatments while others are in their preclinical and clinical trial stages. Further substantiating the success of immunotherapy are several providers in the medical research and pharmaceutical space that boost the efficacy of various strategies and eliminate the risk of therapy failures. Allison and Honjo's discovery of T-cell immune checkpoints CTLA-4 and PD-1, which won the Nobel Prize in Physiology or Medicine was one of the successes that markedly propelled the cancer immunology field. In addition, several others are experimenting with the combination of cancer immunotherapy with functionalized nanosystems as a pivotal treatment strategy for multiple cancer types. Today, the expansion of new immuno-oncology (I-O) programs has increased the demand for optimum healthcare-dedicated predictive models that understand combination immunotherapy against a patient's response and identify novel biomarkers. This edition of Pharma Tech Outlook presents some of the most promising immunotherapy solution providers. The issue includes thought leadership articles from James Riddle, Vice President of research services & strategic consulting at Advarra. This edition also showcases innovative immunotherapy solutions from companies like Sorrento Therapeutics, a leading biopharmaceutical company delivering clinically meaningful therapies to address unmet medical needs.Transforming Treatment Methodologies with Targeted Immunotherapy Copyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.APRIL - 17 - 2023, Vol 09 - Issue 02 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Parley MeadowTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >